OneSpan Q1 revenue $64.8M (+13% YoY); raises FY2024 Adj. EBITDA guidance to $51-55M

OneSpan Inc.

2024-Q1 EPS reported $0.35 revenue$64,843,000

Revenue $64.8M (+13% YoY); subscription revenue $40.0M (+34%); ARR $154.6M (+9%), NRR 107%.
Net income $13.5M ($0.35 diluted EPS) vs net loss $8.4M in Q1 2023; non-GAAP EPS $0.43.
Adjusted EBITDA $19.8M vs $(1.6)M; cash $63.9M, up from $42.5M at Dec 2023.
FY2024 guidance raised: revenue $238-246M, ARR $160-168M, Adj. EBITDA $51-55M (prev. $47-52M).
Interim CEO cites additional $10M annualized cost savings; confident of exceeding prior EBITDA guidance.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

OneSpan Inc. reported the first quarter ended March 31, 2024 results: revenue $64.8 million, net income $13.5 million, or $0.35 per diluted share, EPS $0.35 per diluted share. Guidance raised.

Period: the first quarter ended March 31, 2024
Revenue: $64.8 million
Net income: $13.5 million, or $0.35 per diluted share
EPS: $0.35 per diluted share
Guidance: raised
Result: reported results

Exact text from the filing

by specific reference in such a filing. --- EX-99.1 (EX-99.1) --- OneSpan Reports First Quarter 2024 Financial Results • First quarter revenue grew 13% year-over-year to $64.8 million • First quarter subscription revenue grew 34% year-over-year to $40.0 million • Annual Recurring Revenue (ARR) increased 9% year-over-year to $154.6 million 1 • Net Retention

View on SEC.gov

379 earnings releases filed in the last 30 days. Browse all earnings releases →

OneSpan Inc. filing history →

Source: SEC EDGAR

accession 0001628280-24-019981

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.